About

Pancreatic ductal adenocarcinoma is one of the most lethal cancers worldwide, characterised by poor prognosis and a rising incidence. It is highly destructive due to its particularly aggressive biology, late detection, local and distant spread, and the management challenges it poses. Consequently, it is the fourth most frequent cause of cancer-related deaths worldwide, with a five-year overall survival of less than 8%. Surgical resection is curative, although only about 10-20% of cancers are resectable at diagnosis. Another 20% of patients present with Borderline Resectable Pancreatic Canceror Adenocarcinomas (BRPC). In this cohort of patients diagnosed with pancreatic carcinomas, it is important to identify patients with BRPC from unresectable disease and recognise the role of oncological treatment modalities to increase the resectability rate and improve the long-term survival. This lecture is delivered by Mr Ricky Bhogal, Consultant HPB Surgeon at The Royal Marsden Hospital in London, who is a highly regarded expert in this field.

Topics covered:

• current incidence
• definition
• principles of management
• treatment options
• outcomes and prognosis
• current developments and future advances

Suitable for:

• ST3 and above trainees in General Surgery.
• Speciality Registrars in Surgery with a declared HPB/UGI interest.
• Trainees preparing for the FRCS(Gen Surg) exam.
• Post CCT trainees in HPB surgery.
• Post CCT trainees in UGI surgery.
• Post CCT trainees in General Surgery.
• Speciality Surgeons in General/HPB/UGI Surgery.
• Trainees preparing for European Board exams in General Surgery.

Speaker:

Mr Ricky Bhogal, PhD, FRCS
Consultant HPB Surgeon
The Royal Marsden Hospital, London
Special Interests: Primary liver cancer; Secondary liver cancer; Pancreatic cancer; Biliary tract cancer; Neuroendocrine tumour; Splenic disease; Minimal invasive, laparoscopic, robotic HPB surgery; Translational research.

About the Speaker:

Mr Bhogal trained at the internationally renowned Liver Unit, Birmingham in both HPB and liver transplant surgery. During this period, he was a Wellcome Trust Research Fellow at The University of Birmingham and completed his PhD on liver ischaemia-reperfusion injury in 2011. Following this, he held a NIHR clinical lectureship at the Centre for Liver Research, The University of Birmingham. His research gained wide recognition with the award of several prestigious awards, including The Syme Medal from The Royal College of Surgeons.

Following CCT, he undertook a two-year Senior Fellowship in HPB and liver transplant surgery at The Liver Unit, Birmingham, with an additional focus on surgical oncology and minimal access surgery. He continued his research in parallel, gaining peer reviewed funding, and enhanced this surgical training with sabbaticals at world leading institutions such as The University of Heidelberg, Germany and The Mayo Clinic, Rochester, USA.

As a Consultant at The Royal Marsden Hospital, he is part of a surgical team focused upon performing high volume HPB oncology with a combination of open and minimal access surgical approaches dealing with the full range and complexity of HPB cases.He is continuing his research interests at the ICR and Biomedical Research Centre, and he remains an active member of the liver research group at The University of Birmingham. He has currently published over 60 peer reviewed manuscripts and a number of book chapters.